• Chien-Huang Liao, Chen-Yin Yong, Gi-Ming Lai, Jyh-Ming Chow, Chieh-Fang Cheng, Chia-Lang Fang, Pei-Chun Lin, Chia-Lun Chang, Yu-Mei Zheng, Shuang-En Chuang, Jacqueline Whang-Peng, and Chih-Jung Yao.
• Cancer Center, Wan Fang Hospital, Taipei Medical University, Taipei 11696, Taiwan.
• Am. J. Chin. Med. 2020 Jan 1; 48 (6): 1491-1509.

AbstractAstragalusmembranaceus is the most popular traditional Chinese medicine for managing vital energy deficiency. Its injectable polysaccharide PG2 has been used for relieving cancer-related fatigue, and PG2 has immune-modulatory and anti-inflammatory effects. In this study, we explored the effects of PG2 in lung adenocarcinoma A549 and CL1-2 cells and investigated its anticancer activity, and the results were validated in severe combined immunodeficiency (SCID) mice. Although PG2 did not inhibit the growth of these cells, it dose-dependently suppressed their migration and invasion, accompanied by reduced vimentin and AXL and induced epithelial cadherin (E-cadherin) expression. Regarding the underlying molecular mechanism, PG2 treatment reduced the macrophage migration inhibitory factor (MIF), an inflammatory cytokine that promotes the epithelial-mesenchymal transition and aggressiveness of cancer cells. Consistent with the previous finding that MIF regulates matrix metalloproteinase-13 (MMP-13) and AMP-activated protein kinase (AMPK), treatment with PG2 reduced MMP-13 and activated AMPK in A549 and CL1-2 cells in this study. In SCID mice injected with A549 cells through the tail vein, intraperitoneal injection with PG2 reduced lung and abdominal metastases in parallel with decreased immunohistochemical staining of AXL, vimentin, MMP-13, and MIF in the tumor. Collectively, data revealed a potential application of PG2 in integrative cancer treatment through the suppression of MIF in cancer cells and their aggressiveness.

41 keywords...

hide…